Changes in survival in de novo metastatic cancer in an era of new medicines.
Marianne LuyendijkOtto VisserHedwig M BlommesteinIgnace H J T de HinghFrank J P HoebersAgnes JagerGabe S SonkeElisabeth G E de VriesCarin A Uyl-de GrootSabine SieslingPublished in: Journal of the National Cancer Institute (2023)
Over 30 years, the survival of patients with de novo M1 disease modestly and unevenly increased among cancers. Metastatic cancer still remains a very lethal disease. Next to better treatment options, we call for better preventive measures and early detection to reduce the incidence of metastatic disease.